Sagimet gets FDA OK for late-stage acne trial (SGMT:NASDAQ)
· seekingalpha.com
Sagimet Biosciences (SGMT) stock rises as the FDA clears a Phase 3 clinical trial for the company's acne candidate, denifanstat. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...